

TERA

INDEPENDENT • NON-PROFIT • SCIENCE
FOR PUBLIC HEALTH PROTECTION

23 February 2015

BOARD OF DIRECTORS

Michael Dourson
Toxicology Excellence
for Risk Assessment

Gail Charnley Elliott
HealthRisk Strategies

Mike Fremont
Rivers Unlimited
(Emeritus)

Jennifer L.S. Knaack
Mercer University

Laurie Kraus
Independent Media
Buyer

James C. Rock
TUPE, Inc.

Gregory Romshe
The Procter & Gamble
Company

Jon Seymour
Oxbow, Inc.

Martin L. Stephens
Johns Hopkins School of
Public Health

Philip Tobin
Mercer University

James Wilson
Resources for the Future
(Emeritus)

Chase Wright
Deloitte

SUBJECT: 1,4-Dioxane Status Update


Thank you again for participating in the request for the full 1,4-dioxane drinking water studies conducted by the Japanese Bioassay Research Center (JBRC) in 1988.

We requested the full studies in August 2014 and received them in September 2014. We contacted several companies that could provide us with a full English translation, as well as, have a basic understanding of the science to ensure the correct meaning of the text was captured. The final English translated studies were completed in December 2014. The full studies have been translated into English and each of you received an email with instructions on how to download the studies. Through January 2015 we reviewed the translation and completed a quality assurance of the translations and found no errors in the document. If you have any questions or comments in your review of the translated studies, please let us know.

Currently, we are completing a more in-depth review of the studies and will be developing a report on our interpretations of the studies, especially how they support, or not, the findings presented in "Mode of action analysis for liver tumors from oral 1,4-dioxane exposures and evidence-based dose response assessment" (Reg. Tox. Pharm. 2014. 68(3): 387-401). We will share this report with each of you by March 13th.

Feel free to contact Ms. Patricia Nance, of Toxicology Excellence for Risk Assessment (TERA) at nance@tera.org with any questions. We look forward to hearing from you.

Regards,



Patricia M. Nance
Toxicology Excellence for Risk Assessment



Dr. Michael L. Dourson
Toxicology Excellence for Risk Assessment

*Affiliations are for
identification purposes
only.

GSA Contractor
GS-10F-3069N

TOXICOLOGY EXCELLENCE FOR RISK ASSESSMENT

2300 MONTANA AVENUE, SUITE 409 • CINCINNATI, OHIO 45211
PHONE (513) 542-RISK (7475) • FAX (513) 542-7487 • TERA@TERA.ORG
WWW.TERA.ORG